在乳腺癌中治疗勒普托门病的药物治疗
Rupert Bartsch1, Katarzyna J Jerzak2, Louis Larrouquere3
1Department of Medicine I, Division of Oncology, Medical University Vienna, Vienna, Austria.
Cancer treatment reviews
|December 20, 2023
概括
乳腺癌中勒普托门病 (LMD) 的临床试验很少,导致缺乏现实世界治疗数据. 对于所有带有LMD的乳腺癌亚型,迫切需要更具包容性的随机试验.
科学领域:
- 在瘤学瘤学.
- 神经学 神经学
- 临床试验 临床试验
背景情况:
- 由于临床试验数据有限,乳腺癌患者的勒普托门病 (LMD) 存在重大治疗挑战.
- 患有LMD的患者经常被排除在乳腺癌临床试验之外,这阻碍了对有效治疗方法的理解.
研究的目的:
- 审查和分析LMD乳腺癌目前的治疗策略.
- 突出临床试验证据与LMD管理的现实临床实践之间的差异.
- 发现研究中的差距,并倡导更具包容性的临床试验.
主要方法:
- 对乳腺癌中LMD治疗现有文献的综述.
- 在临床与现实世界的研究中,包括标准,诊断方法和治疗开始时间表的比较.
- 对系统性和导管内药物的有效性报告数据的分析.
主要成果:
- 对于LMD患者的预后仍然很差,总体存活率有限.
- 研究中的治疗方法包括全身使用的图卡丁尼布,特拉斯图祖马布德鲁克斯泰坎和帕克利塔克塞尔特雷瓦提德,以及内治疗的特拉斯图祖马布.
- 目前的试验数据通常仅限于小型单臂研究,主要是对HER2阳性乳腺癌的研究,可变的方法使解释复杂化.
结论:
- 需要进行大规模的随机临床试验,包括包括所有乳腺癌亚型的LMD患者群体的多样性.
- 来自回顾性队列的现实世界数据提供了洞察力,但不能取代前性,受控研究.
- 改进的试验设计和标准化的结果措施对于推进LMD治疗至关重要.
相关概念视频
02:57Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
01:29Drug Delivery: Parenteral Route
545
The parenteral route is a critical method of drug administration. It delivers compounds directly into the systemic circulation and bypasses the gastrointestinal tract. This approach is particularly advantageous for drugs that exhibit poor absorption or instability when administered orally.
There are three primary parenteral routes: intravenous (IV), intramuscular (IM), and subcutaneous (SC). The IV route introduces the drug directly into the bloodstream, ensuring immediate action. The IM route...
There are three primary parenteral routes: intravenous (IV), intramuscular (IM), and subcutaneous (SC). The IV route introduces the drug directly into the bloodstream, ensuring immediate action. The IM route...
545
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
01:22Alzheimer's Disease: Treatment
195
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
195
01:15Drugs that Stabilize Microtubules
2.1K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.1K